China Pharma Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2013
Filed with the SEC on Nov 14, 2013 and accepted by EDGAR at Nov 14, 2013, 16:26 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-07-01 to 2013-09-30 | $8.1m | us-gaap:Revenues |
| Revenue | 9 months2013-01-01 to 2013-09-30 | $24.4m | us-gaap:Revenues |
| Cost of revenue | 3 months2013-07-01 to 2013-09-30 | $5.9m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2013-01-01 to 2013-09-30 | $17.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2013-07-01 to 2013-09-30 | $2.2m | us-gaap:GrossProfit |
| Gross profit | 9 months2013-01-01 to 2013-09-30 | $2.8m | us-gaap:GrossProfit |
| Operating income | 3 months2013-07-01 to 2013-09-30 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2013-01-01 to 2013-09-30 | −$10.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2013-07-01 to 2013-09-30 | −$89.2k | us-gaap:InterestExpense |
| Interest expense | 9 months2013-01-01 to 2013-09-30 | −$263.7k | us-gaap:InterestExpense |
| Income tax | 3 months2013-07-01 to 2013-09-30 | $472.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2013-01-01 to 2013-09-30 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-07-01 to 2013-09-30 | −$2.3m | us-gaap:ProfitLoss |
| Net income | 9 months2013-01-01 to 2013-09-30 | −$9.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-07-01 to 2013-09-30 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2013-01-01 to 2013-09-30 | −$0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2013-07-01 to 2013-09-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2013-01-01 to 2013-09-30 | −$0.22 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2013-01-01 to 2013-09-30 | $3.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2013-01-01 to 2013-09-30 | −$90.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-09-30 | $4.5m | us-gaap:Cash |
| Current assets | At period end2013-09-30 | $98.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2013-09-30 | $162.5m | us-gaap:Assets |
| Current liabilities | At period end2013-09-30 | $13.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-09-30 | $19.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-09-30 | $142.9m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2013-09-30 | 43,579,557 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001010549-13-000676. Last ingested by Listed: Nov 11, 2026, 00:23 ET. Listed shows no prices and gives no investment advice.